Patents Represented by Attorney, Agent or Law Firm Carol A. Stratford
-
Patent number: 5843473Abstract: A method of treating a site of systemic infection which includes administering a therapeutic compound entrapped in liposomes. Also included is a liposomal composition and a method of preparing a liposomal composition for use in concentrating a therapeutic compound to an infected region via the bloodstream. The liposomes, which contain the agent in entrapped form, are composed of vesicle-forming lipids, a vesicle-forming lipid derivatized with hydrophilic biocompatible polymer, and have sizes in a selected size range between 0.07 and 0.2 microns. After parenteral administration, the liposomes are selectively taken up by the infected region within 24-48 hours, for release of entrapped compound into the infected region.Type: GrantFiled: March 27, 1992Date of Patent: December 1, 1998Assignee: SEQUUS Pharmaceuticals, Inc.Inventors: Martin C. Woodle, Irma A.J.M. Bakker-Woudenberg, Francis J. Martin
-
Patent number: 5840502Abstract: The present invention relates to methods of enriching for desired cell population from cell sources, such as body fluids, dispersed tissue specimens and cultured cells. In particular, the present invention relates to the use of a cell-trap centrifugation tube containing a specific density gradient solution adjusted to the specific density of a desired cell population to enrich for the desired cell from a cell source. The tube allows the desired cell population to be collected by decantation after centrifugation to minimize cell loss and maximize efficiency. In addition, the method can be further simplified by density-adjusted cell sorting which uses cell type-specific binding agents such as antibodies and lectins linked to carrier particles to impart a different density to the undesired populations in a more convenient manner. The rapid cell enrichment method described herein has a wide range of diagnostic and therapeutic applications.Type: GrantFiled: August 31, 1994Date of Patent: November 24, 1998Assignee: Activated Cell Therapy, Inc.Inventor: Peter Van Vlasselaer
-
Patent number: 5824506Abstract: Peptide antigens derived from the dengue virus type-2 glycoprotein NS1 are provided. The peptide antigens are specifically immunoreactive with sera from individuals infected with the dengue virus. The antigens are useful as diagnostic tools in determining whether an individual has been or is infected with dengue virus, and for discriminating between infection with dengue virus and infection with related flaviviruses. The antigens are also useful in vaccine compositions for immunizing individuals against infection with the dengue virus.Type: GrantFiled: August 15, 1994Date of Patent: October 20, 1998Assignee: Genelabs Diagnostics PTE. Ltd.Inventors: Lily Chan, Ming Guan
-
Patent number: 5824645Abstract: A method of producing analgesia in nociceptive and neuropathic pain is disclosed. The method includes administering to a subject an omega conopeptide which is characterized by its ability to (a) inhibit electrically stimulated contraction of the guinea pig ileum, and (b) bind selectively to omega conopeptide MVIIA binding sites present in neuronal tissue. Also disclosed are novel omega conotoxin peptides effective in producing analgesia.Type: GrantFiled: November 1, 1996Date of Patent: October 20, 1998Assignee: Neurex CorporationInventors: Alan Justice, Tejinder Singh, Kishor Chandra Gohil, Karen L. Valentino, George P. Miljanich
-
Patent number: 5817650Abstract: Systemic lupus erythematosus (SLE) is treated with dehydroepiandrosterone or its metabolite, sulfate ester, by itself or in combination with other therapies. Substantial improvement in SLE patients is observed during the course of treatment.Type: GrantFiled: April 4, 1997Date of Patent: October 6, 1998Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: James L. McGuire, deceased, Linda R. McGuire, administratrix, Ronald F. Van Vollenhoven, Edgar G. Engleman
-
Patent number: 5814441Abstract: Novel HTLV-I and HTLV-II peptide antigens are disclosed for use in diagnostics assays for screening and confirming HTLV-I and HTLV-II antisera. The peptides are derived from analogous regions of HTLV-I and HTLV-II gp46 envelope proteins, and are differentiated by their immunoreactivity with an HTLV-II specific monoclonal antibody and by HTLV-I and HTLV-II antisera. The peptides are also useful in vaccine compositions.Type: GrantFiled: June 7, 1995Date of Patent: September 29, 1998Assignee: Genelabs Technologies, Inc.Inventors: Gregory R. Reyes, Kenneth G. Hadlock
-
Patent number: 5795864Abstract: Disclosed are formulations effective to stabilize omega conotoxin peptide preparations at elevated temperatures. Novel omega conopeptides also form part of the invention.Type: GrantFiled: June 27, 1995Date of Patent: August 18, 1998Assignee: Neurex CorporationInventors: Gary Arthur Amstutz, Stephen Scott Bowersox, Kishorchandra Gohil, Peter Isadore Adriaenssens, Ramasharma Kristipati
-
Patent number: 5744131Abstract: The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.Type: GrantFiled: June 7, 1995Date of Patent: April 28, 1998Assignee: Genelabs Technologies, Inc.Inventors: Cynthia A. Edwards, Kirk E. Fry, Charles R. Cantor, Beth M. Andrews
-
Patent number: 5738990Abstract: The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.Type: GrantFiled: June 7, 1995Date of Patent: April 14, 1998Assignee: Genelabs Technologies, Inc.Inventors: Cynthia A. Edwards, Kirk E. Fry, Charles R. Cantor, Beth M. Andrews
-
Patent number: 5726014Abstract: The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.Type: GrantFiled: September 17, 1993Date of Patent: March 10, 1998Assignee: Genelabs Technologies, Inc.Inventors: Cynthia A. Edwards, Charles R. Cantor, Beth M. Andrews, Lisa M. Turin
-
Patent number: 5716780Abstract: The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.Type: GrantFiled: June 7, 1995Date of Patent: February 10, 1998Assignee: Genelabs Technologies, Inc.Inventors: Cynthia A. Edwards, Kirk E. Fry, Charles R. Cantor, Beth M. Andrews
-
Patent number: 5693463Abstract: The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.Type: GrantFiled: December 23, 1992Date of Patent: December 2, 1997Assignee: Genelabs Technologies, Inc.Inventors: Cynthia A. Edwards, Kirk E. Fry, Charles R. Cantor, Beth M. Andrews
-
Patent number: 5688503Abstract: Phosphorylated plasminogen activator, such as phosphorylated pro-urokinase (pro-u-PA), which is substantially free from unphosphorylated plasminogen activator, may be obtained by phosphorylating unphosphorylated plasminogen activator with a phosphorylating enzyme or by separating phosphorylated plasminogen activator from a mixture of phosphorylated plasminogen activator and unphosphorylated plasminogen activator. Phosphorylated pro-u-PA, which is substantially free from unphosphorylated pro-u-PA, is converted by plasmin into phosphorylated u-PA. The phosphorylated plasminogen activators such as phosphorylated pro-u-PA, u-PA and t-PA are useful as thrombolytic agents.Type: GrantFiled: May 15, 1995Date of Patent: November 18, 1997Inventors: Francesco Blasi, Maria Patrizia Stoppelli, Maria Rosaria Mastronicola, Karen Gjersing Welinder, Isabel Correas
-
Patent number: 5670316Abstract: The present invention describes the formation of RecA protein catalyzed double-stranded probe:duplex linear target DNA complexes that are stable to deproteinization. The uses of this stable probe:target complex in diagnostic/DNA detection systems in in vitro and in situ DNA hybridization reactions is discussed. The probe:target complexes are also useful for diagnostic application in RecA protein facilitated DNA amplification reactions.Type: GrantFiled: May 25, 1994Date of Patent: September 23, 1997Assignee: Daikin Industries, Ltd.Inventors: Elissa P. Sena, Cornelia J. Calhoun, David A. Zarling
-
Patent number: 5663051Abstract: Disclosed is an apparatus designed to be used for enriching specific cell types from cell mixtures. The apparatus includes a centrifugable device that includes a constriction defining a lower region and a defined cell separation medium. The constriction prevents mixing between the upper and lower portions of the device. Also disclosed are methods that use precisely defined cell separation media to isolate specific cells from cell mixtures, including CD34.sup.+ hematopoietic progenitor cells from blood or bone marrow, nucleated fetal cells from maternal blood, specific tumor cells, dendritic cells, natural killer cells, and natural suppressor cells from various body fluids, and for enrichment or depletion of T cell lymphocytes. Also disclosed is a density adjusted cell separation technique used to augment the above apparatus and enrichment methods. The apparatus and enrichment methods are useful in various diagnostic and therapeutic regimens.Type: GrantFiled: December 11, 1995Date of Patent: September 2, 1997Assignee: Activated Cell Therapy, Inc.Inventor: Peter Van Vlasselaer
-
Patent number: 5648223Abstract: The present invention relates to methods of enriching breast tumor cells from a patient's body fluids. In particular, it relates to the use of a cell-trap centrifugation tube containing a specific density gradient solution adjusted to a specific density to enrich for breast tumor cells from a cell mixture. The tube allows the desired cell population to be collected by decantation after centrifugation to minimize cell loss and maximize efficiency. In addition, the method can be further simplified by density-adjusted cell sorting which uses cell type-specific binding agents such as antibodies and lectins linked to carrier particles to impart a different density to the non-tumor or tumor cell populations allowing the breast tumor cells to be separated from the non-tumor cells in a more convenient manner.Type: GrantFiled: August 31, 1994Date of Patent: July 15, 1997Assignee: Activated Cell Therapy, Inc.Inventor: Peter Van Vlasselaer
-
Patent number: 5646004Abstract: The present invention relates to methods of enriching fetal cells from maternal body fluids. In particular, it relates to the use of a cell-trap centrifugation tube containing a gradient solution adjusted to a specific density to enrich for fetal nucleated red blood cells from maternal blood. The tube allows the desired cell population to be collected by decantation after centrifugation to minimize cell loss and maximize efficiency. In addition, the method can be further simplified by density-adjusted cell sorting which uses cell type-specific binding agents such as antibodies and lectins linked to carrier particles to impart a different density to undesired cell populations allowing the fetal cells to be separated during centrifugation in a more convenient manner. The rapid fetal cell enrichment method described herein has a wide range of applications, including but not limited to, gender determination and prenatal diagnosis of genetic diseases without the use of invasive procedures.Type: GrantFiled: August 31, 1994Date of Patent: July 8, 1997Assignee: Activated Cell Therapy, Inc.Inventor: Peter Van Vlasselaer
-
Patent number: 5646185Abstract: Disclosed is a method of treating a solid tumor, where the tumor contains regions of hypoxic cells, either because of poor vascularization in the tumor or because of vasoconstrictive or vaso-occlusive measures brought to bear on the tumor. The method includes administering to a subject, a compound effective to activate protein kinase C activity in the cells of the tumor, via a route effective to direct the compound to such regions of hypoxia in the tumor. Preferred compounds include phorbol esters, diacylglycerols, and thapsigargin. Also disclosed is a vaso-occlusive composition containing a protein kinase C activator, for use in the treatment method.Type: GrantFiled: October 14, 1993Date of Patent: July 8, 1997Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Amato J. Giaccia, Albert C. Koong
-
Patent number: 5641760Abstract: A method of treating Candida albicans infection is disclosed. In one embodiment, for treatment of oral or vaginal infection, the treatment is by topical application of a composition of conjugates that are each composed of a carrier structure and multiple .beta.GalNac(1-4).beta.Gal moieties attached to the structure. In another embodiment, for treatment of systemic infection, the treatment is by parenteral administration of a humanized form of a mouse monoclonal antibody produced by mouse hybridoma cell line Fm16 or cell line PK99H.Type: GrantFiled: June 17, 1994Date of Patent: June 24, 1997Assignee: Pence, Inc.Inventors: Lei Yu, Kok Kheong Lee, Hasmukh B. Sheth, Randall T. Irvin, Robert S. Hodges
-
Patent number: 5612036Abstract: Treatment and diagnosis of P. aeruginosa infection or colonization is achieved in accordance with this invention by the discovery of a polypeptide which is smaller than the naturally occurring P. aeruginosa pillin protein. The pure polypeptide comprises at least one amino acid residue sequence containing about twelve amino acid residues and up to about twenty amino acid residues that define a sequence capable of immunologically mimicking an antigenic determinant cite of P. aeruginosa pilin. This amino acid residue sequence can repeat as a unit one or more times in the same polypeptide molecule. More than one of such repeating units and more than one repeating unit of the same type can be present in a single polypeptide molecule. The polypeptides act an antigens or immunogens and antibodies may be raised to the immunogens and a vaccine prepared suitable for the prevention of P. aeruginosa infection.Type: GrantFiled: August 25, 1995Date of Patent: March 18, 1997Assignee: The Governors of the University of AlbertaInventors: Robert S. Hodges, William Paranchych, Kok K. Lee, Sastry A. Parimi, Randall T. Irvin, Peter C. Doig